Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-05-10 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于2020年限制性股票激励计划第一个归属期第二次归属结果暨股份上市的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the second vesting result of the company's 2020 restricted stock incentive plan and the listing of the vested shares. It details the number of shares vested, the listing date, the decision-making process, and the impact on share capital. The document is relatively short (3,679 characters) and focuses on the announcement of the stock vesting and listing event rather than providing a full report or detailed financial statements. It is not an annual or interim report, nor a management discussion or earnings release. It is a formal announcement about share issuance related to a stock incentive plan, which fits best under the category of Share Issue/Capital Change (SHA).
2022-05-10 Chinese
美迪西：关于疫情防控期间参加2021年年度股东大会相关注意事项的提示性公告
AGM Information Classification · 95% confidence The document is a notice from Shanghai Medicilon Biopharmaceutical Co., Ltd. regarding the arrangements and precautions for attending the 2021 Annual General Meeting (AGM) during the COVID-19 pandemic. It discusses changes to the meeting format, voting methods, and health safety measures. It does not contain financial data, results, or detailed reports but rather logistical information about the AGM. The document is short (1135 characters) and serves as an announcement related to the AGM rather than the AGM materials themselves. Therefore, it fits the category of AGM Information (AGM-R).
2022-05-09 Chinese
美迪西：2021年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled "2021 年年度股东大会会议资料" which translates to "2021 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, meeting instructions, reports from the board, supervisory board, and independent directors, as well as voting procedures and other materials typically distributed to shareholders before or during an AGM. The content includes multiple proposals to be voted on, reports for shareholder review, and procedural details for the meeting. The document length is about 15,000 characters, indicating it is a full set of meeting materials rather than a brief announcement. There is no indication that this is a transcript, earnings release, or other report type. Therefore, this document fits the category of AGM Information (AGM-R).
2022-05-09 Chinese
美迪西：关于召开2021年度暨2022年第一季度业绩说明会的公告
Call Transcript Classification · 90% confidence The document is an announcement about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2021 annual and 2022 first quarter results. It provides the meeting time, location, participation method, and contact information. It references that the 2021 annual report and 2022 Q1 report have already been published, but this document itself is not the report or the transcript of the call. It is a notice about the earnings call event, which aligns with the category of a Call Transcript (CT) announcement or an Earnings Release (ER) announcement. However, since it is specifically about the earnings explanation meeting (业绩说明会), which is a type of earnings call, and it is announcing the event rather than providing the transcript or financial highlights, the best fit is Call Transcript (CT) category as it relates to the earnings call event. The document length is short (1645 characters), and it is not the transcript itself but an announcement of the meeting. Given the options, CT is the closest category for an earnings call announcement. Confidence is high due to clear references to earnings explanation meeting and detailed meeting logistics.
2022-04-28 Chinese
美迪西：2022年第一季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report explicitly states it is unaudited and includes comprehensive financial metrics and analysis for the quarter ending March 31, 2022. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 12,771 characters long, which is substantial and contains the full report, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2022
2022-04-28 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2022年度向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed issuance sponsorship report (发行保荐书) by a securities company (广发证券股份有限公司) for Shanghai Medicilon Inc.'s 2022 private placement of A shares. It includes extensive information about the issuer, the underwriting institution, legal compliance, financial data, shareholder structure, and regulatory adherence. The document is not a simple announcement but a comprehensive report related to a capital raising event through a private placement of shares. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive content about the issuance process, regulatory compliance, and financial data related to the capital raising. Therefore, the correct classification is CAP.
2022-04-26 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.